ABSTRACT
The morbidity and mortality related to metastatic breast cancer remains high, a contributing factor to this being difficulty in accurate cancer detection and staging. Functional imaging approaches are now being increasingly used in oncological management, the principal advantage relative to anatomical imaging being that sites of active disease are accurately assessed. A particularly exciting development in recent years has been that of the advent of positron emission tomography/computed tomography (PET/CT) scanners that provide functional information regarding disease status (defining sites of active/inactive disease) combined with the anatomical definition of CT.
